Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;25(6):355-357.
doi: 10.3747/co.25.4587. Epub 2018 Dec 1.

Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others"

B Basulaiman  1 , A Awan  1 , J F Hilton  1   2 , M Clemons  1   2
Affiliations
Editorial

Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others"

B Basulaiman et al. Curr Oncol. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: BB has attended advisor board meetings for Roche, Amgen, and Novartis; AA has attended advisor boards for Novartis; JFH has served as an advisory consultant for Bristol–Myers Squibb, Eli Lilly, Merck, Novartis, Roche, Pfizer, and as a member of a data monitoring committee for Bristol–Myers Squibb; MC has served as an advisory board member for Helsinn.

Similar articles

See all similar articles

References

    1. Ornstein C, Thomas K. Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals [Web article] The New York Times. 2018. Sep 8, [Available at: https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-s...; cited 20 September 2018]
    1. Angell M. Transparency Hasn’t Stopped Drug Companies from Corrupting Medical Research [Web article] The New York Times. 2018. Sep 14, [Available at: https://www.nytimes.com/2018/09/14/opinion/jose-baselgare-search-disclos...; cited 20 September 2018]
    1. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer. N Engl J Med. 2017;377:122–31. doi: 10.1056/NEJMoa1703643. - DOI - PMC - PubMed
    1. Miller KD. Questioning our aphinity for more. N Engl J Med. 2017;377:186–7. doi: 10.1056/NEJMe1706150. - DOI - PubMed
    1. Baselga J, Gelmon KA, Verma S, et al. Phase ii trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138–44. doi: 10.1200/JCO.2009.24.2024. - DOI - PMC - PubMed

Publication types

LinkOut - more resources